Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT06023589RecruitingPhase 3
Testing tezepelumab for kids with severe asthma
This study tests if tezepelumab can help reduce severe asthma attacks in children ages 5 to 11. It compares the drug to a placebo (a dummy treatment) to see if it is safe and effective.
Montgomery, AlabamaAges 5–11 - NCT05982223Recruiting
Integrative medicine for lymphoma survivors in early remission
This study explores how integrative medicine (such as nutrition, mind-body practices, or supplements) might help people recover and improve well-being after finishing lymphoma treatment. It is for patients who are in remission for less than one year.
HaifaAges 18 years+ - NCT05998642RecruitingPhase 2
Ibrutinib combo for newly diagnosed brain lymphoma
This trial tests a combination of ibrutinib, methotrexate, and rituximab for people with newly diagnosed primary CNS lymphoma who cannot have a stem cell transplant. It aims to see if this drug combination can effectively treat the disease.
Calgary, AlbertaAges 18 years+ - NCT05999877Recruiting
Acalabrutinib real-world study for chronic lymphocytic leukemia
This study looks at how acalabrutinib, a targeted therapy for chronic lymphocytic leukemia (CLL), works in real-life settings in Spain. It aims to see how well it helps people who are starting treatment for the first time or switching due to side effects.
Almería, AndalusiaAges 18 years+ - NCT05989698Recruiting
Validating a wearable cough monitor (C-mo)
This study tests a wearable device (C-mo) that monitors coughing. It is for people of all ages who are currently coughing and can cooperate with wearing a small sensor on their belly for a short time.
AlfenaAges 2 years+ - NCT05974150Recruiting
Remote symptom monitoring for several blood and cancer types
This study checks how well remote (at-home) symptom check-ins work for people with certain cancers. It may help patients and clinicians spot problems earlier and improve day-to-day care during treatment and beyond.
New Haven, ConnecticutAges 18 years+ - NCT05984147RecruitingPhase 1
Study of oral drug AUR108 for advanced lymphoma
This trial tests an experimental oral drug called AUR108 for people with advanced lymphoma that has come back after at least two prior treatments. The goal is to see if the drug is safe and if it can help shrink or control the lymphoma.
Visakhapatnam, Andhra PradeshAges 18–99 - NCT05979051RecruitingPhase 2/Phase 3
Study of SHR-1703 for eosinophilic granulomatosis with polyangiitis (EGPA)
This trial tests a new medicine called SHR-1703 for people with EGPA that has come back or is hard to treat. It aims to see if the drug can help control the disease better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Duarte, CaliforniaAges Any age - NCT06001138Enrolling by invitation
FutureMS-2: A Follow-Up Study for MS
This study follows up with people who have Multiple Sclerosis and were in the earlier FutureMS study. It uses MRI scans to learn more about MS and find better ways to treat it.
AberdeenAges 18 years+ - NCT05998291Enrolling by invitation
Dermatitis herpetiformis not helped by gluten-free diet
This trial studies two groups of people with dermatitis herpetiformis. One group has a rash that still appears even after following a strict gluten-free diet for at least 3 years. The other group responds well to the diet. The study will compare them to learn more and find better ways to help.
TampereAges 18 years+ - NCT05982925Recruiting
Brain imaging study in multiple sclerosis
This study uses MRI scans to look at how multiple sclerosis affects the outer layer of the brain over time. It aims to learn more about the disease to help improve future treatments.
New York, New YorkAges 18 years+ - NCT05991115Recruiting
Hospital to home study for children with asthma
This study helps families whose child is in the hospital for asthma. It aims to make the transition home smoother and reduce asthma-related health differences.
Washington D.C., District of ColumbiaAges 4–12 - NCT05976555RecruitingPhase 1
CAR T-cell therapy for relapsed myeloma after multiple treatments
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
Milwaukee, WisconsinAges 18–80 - NCT05976997RecruitingPhase 2
Test duvelisib plus chidamide for newly diagnosed PTCL
This trial studies whether the combination of duvelisib and chidamide can treat newly diagnosed peripheral T-cell lymphoma (PTCL). Because it is a single-arm study, everyone gets the treatment, and the team monitors response and safety.
Wuhan, HubeiAges 18–70 - NCT05996185RecruitingPhase 2
Study of mogamulizumab plus chemotherapy for T-cell lymphoma
This trial is testing a drug called mogamulizumab combined with standard chemotherapy (DA-EPOCH or CHOEP) for people with aggressive T-cell lymphoma. It aims to see if the combination is safe and works better than chemotherapy alone.
New Haven, ConnecticutAges 18 years+ - NCT05996016Recruiting
Gut and vaginal bacteria in HIV-positive women
This study looks at the types of bacteria living in the gut and vagina of women with HIV, including pregnant women. It aims to understand how these bacteria might affect health.
Beijing, Beijing MunicipalityAges 14 years+ - NCT05996731Recruiting
Using RNA tests to help diagnose rare genetic diseases
This study uses RNA sequencing to find genetic causes of rare diseases that standard DNA tests might miss. It may help people who have symptoms of a rare disease but no clear genetic diagnosis yet.
Ranica, BGAges Any age - NCT05994976Recruiting
Collecting skin samples from people with skin conditions
This study collects skin samples (like small biopsies or swabs) from people with certain skin conditions and from healthy volunteers. The samples help researchers learn more about these conditions and may lead to better treatments.
Montreal, QuebecAges 18 years+ - NCT05973734Enrolling by invitationPhase 1
Islet transplant with immune cells to treat type 1 diabetes
This Phase 1 study tests a new immune-system strategy around islet transplantation (or donor bone marrow therapy) to improve control of type 1 diabetes and reduce dangerous low blood sugar. It mainly aims to see if the approach is safe and helpful in people with long-standing, difficult-to-manage diabetes.
Palo Alto, CaliforniaAges 18–70 - NCT05976763RecruitingPhase 3
Testing continuous vs. intermittent zanubrutinib for older adults with mantle cell lymphoma
This trial tests whether taking the targeted drug zanubrutinib continuously is better than taking it on a schedule with breaks for older adults with untreated mantle cell lymphoma. The goal is to find a treatment that works while reducing side effects.
Little Rock, ArkansasAges 60 years+ - NCT05992532Recruiting
Study of rare enzyme disorders in monoclonal gammopathy or myeloma
This study looks for two rare inherited disorders—Gaucher disease and acid sphingomyelinase deficiency (ASMD)—in people who already have a blood condition like monoclonal gammopathy (abnormal protein) or multiple myeloma. If you have an enlarged spleen or low platelets, you may be eligible to help researchers understand if these rare diseases are more common in this group.
Vitoria-Gasteiz, AlavaAges 18–99 - NCT05977673RecruitingPhase 2
Tislelizumab for untreated Hodgkin lymphoma when chemo isn’t suitable
This Phase 2 trial tests tislelizumab (an immune therapy) in people with newly diagnosed classical Hodgkin lymphoma who cannot safely get standard chemotherapy. It aims to see how well the treatment works and whether it is safe for older adults and others with health limits.
Alessandria, ITAges 65 years+ - NCT05996627RecruitingPhase 2
Belumosudil for early treatment of chronic graft-versus-host disease
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
Duarte, CaliforniaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.